Regenerex Pharma Reports $1.1 Million Net Loss, Focuses on Wound Care Market Expansion

Regenerex Pharma, Inc. reported a net loss of $1.1 million for the nine months ending December 31, 2024, a significant decrease from the $3.25 million loss recorded during the same period in 2023. The company did not generate any revenue in either period. The reduction in losses is attributed to decreased research and development expenses, lower stock-based compensation, and reduced administrative costs, although these were partially offset by increased payroll and interest expenses. The basic and diluted loss per share remained at $0.00 for both periods.

The company's total assets decreased to $646,860 as of December 31, 2024, down from $766,680 at the end of the previous fiscal period. Current liabilities surged to $5.16 million, compared to $3.84 million in March 2024, primarily due to increases in accounts payable and accrued compensation. The stockholders' deficit also widened to $5.05 million from $4.06 million, reflecting ongoing financial challenges.

Strategically, Regenerex has focused on expanding its product offerings in the wound care market. The company has entered into agreements to acquire intellectual property related to wound healing technologies, including a $2.4 million note payable for technology platforms purchased in August 2023. Additionally, Regenerex is developing managed care agreements with southeastern states to manage Medicaid wound care patients, which could enhance its market presence. The company is also negotiating with distributors in the Middle East to broaden its geographic reach.

Operationally, Regenerex has not reported any customer counts or user statistics, as it has yet to generate revenue from its product lines. The company has engaged in various financing activities, raising $340,617 in the nine months ended December 31, 2024, primarily through notes payable and the sale of common stock. The total cash used in operating activities decreased to $340,651 from $393,113 in the prior year, indicating improved cash management.

Looking ahead, Regenerex's management acknowledges the need for significant capital to launch its business and reduce liabilities. The company plans to actively seek additional funding to support its operations and product development. However, management has expressed uncertainty regarding its ability to raise sufficient capital, which raises concerns about the company's ability to continue as a going concern. The outlook remains cautious as Regenerex navigates its financial challenges while attempting to establish a foothold in the competitive wound care market.